HEALTH PLAN POLICY

Policy Title: Gene Expression Profiling for Coronary Artery Disease
Policy Number: MUM55
Revision: New

Department: Medical Management
Sub-Department: Utilization Management

Applies to Product Lines:
- Medicaid
- USFHP
- Children’s Health Insurance Plan
- Commercial Insured
- Health Insurance Exchange
- Medicare
- Non Insured Business

Origination/Effective Date: 10/09/2019
Reviewed Date(s):
Revision Date(s):

SCOPE:

This policy addresses genetic expression profiling (GEP) for patients with coronary artery disease (CAD).

DEFINITIONS AND ACRONYMS:

- Communicable Disease Center (CDC)
- Coronary Artery Disease (CAD)
- Gene Expression Profiling (GEP)

POLICY:

GEP for CAD is investigational and not medically necessary.

RATIONALE:

CAD accounts for 370,000 deaths per year. The gold standard for diagnostic purposes is coronary angiography. This is an invasive procedure that increases risk. In an effort to decrease procedural risk, GEP is a non-invasive technique employed rather than angiography.

There is a commercially available test – Corus CAD. This test is not FDA approved. The test is somewhat limited in its application given it can only be used in non-diabetics. CAD has a high degree of association with diabetes. Although Corus CAD has some diagnostic value, there is no literature based evidence indicating improve clinical outcomes. Several other non-invasive studies are available to assist physicians in identifying CAD.

REFERENCES:

- CDC 2017 – Differences in Women Compared to Men Relative to CAD
- CDC 2015 – Symptoms of CAD
- Ayerbe 2016 – Validated Risk Prediction Tools
HEALTH PLAN POLICY

Policy Title: Gene Expression Profiling for Coronary Artery Disease
Policy Number: MUM55
Revision: New

RELATED DOCUMENTS:
None

Nancy Horstmann
Chief Executive Officer Health Plans
10/21/19
Date

David Engleking, M.D.
Medical Director
10/5/19
Date

REVISION HISTORY:

<table>
<thead>
<tr>
<th>Revision</th>
<th>Date</th>
<th>Description of Change</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>10/09/2019</td>
<td>Initial release.</td>
<td>Executive Leadership</td>
</tr>
</tbody>
</table>

Page 2 of 2